2-(6-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)acetic acid | 1262007-19-1

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 哈马拉生物碱
• 英文名称: 2-(6-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)acetic acid
• 英文别名: 2-[6-[[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy]-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl]acetic acid
• CAS: 1262007-19-1
• 化学式: C₂₆H₂₇F₃N₂O₃
• 分子量: 472.507
• InChiKey: ISBCPWVJRHMKFI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  34
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  74.4
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  2-(6-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)acetic acid 生成 2-[(1S)-6-[[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy]-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl]acetic acid 、 2-[(1R)-6-[[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy]-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl]acetic acid
  参考文献：
  名称：

  Design and synthesis of new tricyclic indoles as potent modulators of the S1P1 receptor

  摘要：

  Modulators of S1P(1) have proven utility for the treatment of autoimmune disease and efforts to identify new agents with improved safety and pharmacokinetic parameters are ongoing. Several new S1P(1) chemotypes were designed and optimized for potency and oral bioavailability. These new agents are characterized by a 'tricyclic fused indole array' and are highly potent agonists of the S1P(1) receptor. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.11.089
• 作为产物：
  描述：

  5-苄氧基色胺 在 盐酸 、 palladium on activated charcoal 、 氢气 、 caesium carbonate 、 三氟乙酸 、 lithium hydroxide 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 水 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 生成 2-(6-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)acetic acid
  参考文献：
  名称：

  Design and synthesis of new tricyclic indoles as potent modulators of the S1P1 receptor

  摘要：

  Modulators of S1P(1) have proven utility for the treatment of autoimmune disease and efforts to identify new agents with improved safety and pharmacokinetic parameters are ongoing. Several new S1P(1) chemotypes were designed and optimized for potency and oral bioavailability. These new agents are characterized by a 'tricyclic fused indole array' and are highly potent agonists of the S1P(1) receptor. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.11.089

文献信息

• COMPOSITIONS FOR BINDING SPHINGOSINE-1-PHOSPHATE RECEPTOR 1 (S1P1), IMAGING OF S1P1, AND METHODS OF USE THEREOF
  申请人：Tu Zhude

  公开号：US20190002450A1

  公开（公告）日：2019-01-03

  Among the various aspects of the present disclosure is the provision of a compositions for binding sphingosine-1-phosphate receptor 1 (S1P1), imaging of S1P1, and methods of use thereof. Provided are imaging agents for imaging S1P1 and S1P1 associated diseases, disorders, and conditions. Also provided are therapeutic compositions and methods for the treatment of S1P1 associated diseases, disorders, and conditions.

  本公开的各个方面之一是提供一种用于结合鞘氨醇-1-磷酸受体1（S1P1）、S1P1成像以及使用方法的组合物。提供了用于成像S1P1和S1P1相关疾病、紊乱和症状的成像剂。还提供了用于治疗S1P1相关疾病、紊乱和症状的治疗组合物和方法。
• Compositions for binding sphingosine-1-phosphate receptor 1 (S1P1), imaging of S1P1, and methods of use thereof
  申请人：Tu Zhude

  公开号：US10676467B2

  公开（公告）日：2020-06-09

  Among the various aspects of the present disclosure is the provision of a compositions for binding sphingosine-1-phosphate receptor 1 (S1P1), imaging of S1P1, and methods of use thereof. Provided are imaging agents for imaging S1P1 and S1P1 associated diseases, disorders, and conditions. Also provided are therapeutic compositions and methods for the treatment of S1P1 associated diseases, disorders, and conditions.

  在本公开的各个方面中，提供了一种用于结合鞘氨醇-1-磷酸受体 1（S1P1）的组合物、S1P1 的成像及其使用方法。提供了用于成像 S1P1 和 S1P1 相关疾病、失调和病症的成像剂。还提供了用于治疗 S1P1 相关疾病、失调和病症的治疗组合物和方法。
• [EN] MODULATORS OF THE SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO<br/>[FR] MODULATEURS DU RÉCEPTEUR SPHINGOSINE-1-PHOSPHATE (S1P) UTILES POUR LE TRAITEMENT DE TROUBLES ASSOCIÉS À CEUX-CI
  申请人：ARENA PHARM INC

  公开号：WO2011005295A1

  公开（公告）日：2011-01-13

  The present invention relates to certain compounds of Formula (Ia) and pharmaceutically acceptable salts, solvates, and hydrates thereof, which exhibit useful pharmacological properties, for example, as agonists of the S1P1 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of S1P1 receptor-associated disorders, for example, psoriasis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, type I diabetes, acne, myocardial ischemia-reperfusion injury, hypertensive nephropathy, glomerulosclerosis, gastritis, polymyositis, thyroiditis, vitiligo, hepatitis, biliary cirrhosis, microbial infections and associated diseases, viral infections and associated diseases, diseases and disorders mediated by lymphocytes, auto immune diseases, inflammatory diseases, and cancer.
• Design and synthesis of new tricyclic indoles as potent modulators of the S1P1 receptor
  作者：Daniel J. Buzard、Thomas O. Schrader、Xiuwen Zhu、Juerg Lehmann、Ben Johnson、Michelle Kasem、Sun Hee Kim、Andrew Kawasaki、Luis Lopez、Jeanne Moody、Sangdon Han、Yinghong Gao、Jeff Edwards、Jeremy Barden、Jayant Thatte、Joel Gatlin、Robert M. Jones

  DOI：10.1016/j.bmcl.2014.11.089

  日期：2015.2

  Modulators of S1P(1) have proven utility for the treatment of autoimmune disease and efforts to identify new agents with improved safety and pharmacokinetic parameters are ongoing. Several new S1P(1) chemotypes were designed and optimized for potency and oral bioavailability. These new agents are characterized by a 'tricyclic fused indole array' and are highly potent agonists of the S1P(1) receptor. (C) 2014 Elsevier Ltd. All rights reserved.